Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
United States
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois Last updated December 2025